FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Assessment of positive iron balance in end-stage renal disease: Could hepcidin-25 be useful?

Authorized Users Only
2021
Authors
Savković, Miljan
Simić-Ogrizović, Sanja
Dopsaj, Violeta
Article (Published version)
Metadata
Show full item record
Abstract
Introduction: The aim of our study was to examine the relationship of hepcidin-25 with red blood cell and reticulocyte indices and to evaluate the diagnostic properties of hepcidin-25 in the assessment of positive iron balance in end-stage renal disease (ESRD) patients. Methods: Eighty anemic ESRD patients (hemoglobin < 110 g/L) were classified as having iron deficiency (ID, N = 20), iron sufficiency (IS, N = 29), and positive iron balance (PB, N = 31) using the conventional biomarkers for iron status evaluation. Hepcidin-25 was determined by a chemiluminescent direct ELISA. Results: Hepcidin-25 was significantly negatively correlated with the proportion of hypochromic erythrocytes (%HYPO) (P =.034) and immature reticulocyte fraction (P =.010) in ID and with the absolute reticulocyte concentration in ID (P =.048) and PB (P =.040). In multivariate models, hepcidin-25 was independently negatively associated with the mean reticulocyte hemoglobin content (CHr; β = −0.493, P =.004) and red ...blood cell size factor (RSf) (β = −0.334, P =.036) only in the PB group. The best hepcidin-25 value to exclude PB was 66.13 µg/L, showing a sensitivity of 61.3%, a specificity of 75.5%, and an AUC of 0.808. Conclusion: Our results suggest that hepcidin-25 levels are independently negatively associated with the iron demand for the most recent erythropoiesis only in PB. Hepcidin-25 performed acceptable in discriminating anemic ESRD patients with positive iron balance and may prove to be a useful additional tool in the evaluation of iron status.

Keywords:
anemia / chronic kidney disease / hepcidin / hypochromic red blood cell / reticulocyte hemoglobin content
Source:
International Journal of Laboratory Hematology, 2021, 43, 5, 1159-1167
Publisher:
  • John Wiley & Sons Ltd
Funding / projects:
  • Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 200161 (University of Belgrade, Faculty of Pharmacy) (RS-200161)

DOI: 10.1111/ijlh.13539

ISSN: 1751-5521

WoS: 000638216700001

Scopus: 2-s2.0-85104082896
[ Google Scholar ]
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3903
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Savković, Miljan
AU  - Simić-Ogrizović, Sanja
AU  - Dopsaj, Violeta
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3903
AB  - Introduction: The aim of our study was to examine the relationship of hepcidin-25 with red blood cell and reticulocyte indices and to evaluate the diagnostic properties of hepcidin-25 in the assessment of positive iron balance in end-stage renal disease (ESRD) patients. Methods: Eighty anemic ESRD patients (hemoglobin < 110 g/L) were classified as having iron deficiency (ID, N = 20), iron sufficiency (IS, N = 29), and positive iron balance (PB, N = 31) using the conventional biomarkers for iron status evaluation. Hepcidin-25 was determined by a chemiluminescent direct ELISA. Results: Hepcidin-25 was significantly negatively correlated with the proportion of hypochromic erythrocytes (%HYPO) (P =.034) and immature reticulocyte fraction (P =.010) in ID and with the absolute reticulocyte concentration in ID (P =.048) and PB (P =.040). In multivariate models, hepcidin-25 was independently negatively associated with the mean reticulocyte hemoglobin content (CHr; β = −0.493, P =.004) and red blood cell size factor (RSf) (β = −0.334, P =.036) only in the PB group. The best hepcidin-25 value to exclude PB was 66.13 µg/L, showing a sensitivity of 61.3%, a specificity of 75.5%, and an AUC of 0.808. Conclusion: Our results suggest that hepcidin-25 levels are independently negatively associated with the iron demand for the most recent erythropoiesis only in PB. Hepcidin-25 performed acceptable in discriminating anemic ESRD patients with positive iron balance and may prove to be a useful additional tool in the evaluation of iron status.
PB  - John Wiley & Sons Ltd
T2  - International Journal of Laboratory Hematology
T1  - Assessment of positive iron balance in end-stage renal disease: Could hepcidin-25 be useful?
VL  - 43
IS  - 5
SP  - 1159
EP  - 1167
DO  - 10.1111/ijlh.13539
ER  - 
@article{
author = "Savković, Miljan and Simić-Ogrizović, Sanja and Dopsaj, Violeta",
year = "2021",
abstract = "Introduction: The aim of our study was to examine the relationship of hepcidin-25 with red blood cell and reticulocyte indices and to evaluate the diagnostic properties of hepcidin-25 in the assessment of positive iron balance in end-stage renal disease (ESRD) patients. Methods: Eighty anemic ESRD patients (hemoglobin < 110 g/L) were classified as having iron deficiency (ID, N = 20), iron sufficiency (IS, N = 29), and positive iron balance (PB, N = 31) using the conventional biomarkers for iron status evaluation. Hepcidin-25 was determined by a chemiluminescent direct ELISA. Results: Hepcidin-25 was significantly negatively correlated with the proportion of hypochromic erythrocytes (%HYPO) (P =.034) and immature reticulocyte fraction (P =.010) in ID and with the absolute reticulocyte concentration in ID (P =.048) and PB (P =.040). In multivariate models, hepcidin-25 was independently negatively associated with the mean reticulocyte hemoglobin content (CHr; β = −0.493, P =.004) and red blood cell size factor (RSf) (β = −0.334, P =.036) only in the PB group. The best hepcidin-25 value to exclude PB was 66.13 µg/L, showing a sensitivity of 61.3%, a specificity of 75.5%, and an AUC of 0.808. Conclusion: Our results suggest that hepcidin-25 levels are independently negatively associated with the iron demand for the most recent erythropoiesis only in PB. Hepcidin-25 performed acceptable in discriminating anemic ESRD patients with positive iron balance and may prove to be a useful additional tool in the evaluation of iron status.",
publisher = "John Wiley & Sons Ltd",
journal = "International Journal of Laboratory Hematology",
title = "Assessment of positive iron balance in end-stage renal disease: Could hepcidin-25 be useful?",
volume = "43",
number = "5",
pages = "1159-1167",
doi = "10.1111/ijlh.13539"
}
Savković, M., Simić-Ogrizović, S.,& Dopsaj, V.. (2021). Assessment of positive iron balance in end-stage renal disease: Could hepcidin-25 be useful?. in International Journal of Laboratory Hematology
John Wiley & Sons Ltd., 43(5), 1159-1167.
https://doi.org/10.1111/ijlh.13539
Savković M, Simić-Ogrizović S, Dopsaj V. Assessment of positive iron balance in end-stage renal disease: Could hepcidin-25 be useful?. in International Journal of Laboratory Hematology. 2021;43(5):1159-1167.
doi:10.1111/ijlh.13539 .
Savković, Miljan, Simić-Ogrizović, Sanja, Dopsaj, Violeta, "Assessment of positive iron balance in end-stage renal disease: Could hepcidin-25 be useful?" in International Journal of Laboratory Hematology, 43, no. 5 (2021):1159-1167,
https://doi.org/10.1111/ijlh.13539 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB